

IN THE SPECIFICATION:

Please amend the Specification in the paragraph bridging Pages 12 to 13 to read as follows:

--Very particular preference is given to ~~Novozym® 435,~~
NOVOZYM® 435, 525 (commercially available from Novo, Denmark),
~~Chirazym®~~ CHIRAZYM® L2, E1, E2 and L7 (commercially available
from Boehringer Mannheim, Germany) as enzyme. NOVOZYM® is a
trademark for a product, the active ingredient of which is a
lipase of *Candida antarctica* B. CHIRAZYM® is a trademark for a
product, in which the active ingredient is as follows:

L2 is for Lipase from *Candida antarctica* B;

E1 is for Esterase from pig liver;

E2 is for Esterase from pig liver; and

L7 is for Lipase from porcine pancreas. --

Please amend the Specification on Page 13 by amending the paragraph in lines 6 to 16 to read as follows:

--An immobilized form can be prepared in a manner known per se. This is possible, for example, by the enzyme being dissolved in a buffer at a suitable pH and then being passively absorbed onto the carrier such as, for example, diatomaceous earth (CELITE®) ~~(Celite®)~~, activated carbon, alumina, silica gel, kieselguhr,

monodisperse soluble organosiloxane particles or resins (e.g. AMBERLITE®, DOWEX®) (~~e.g. Amberlite®, Dowex®~~). An alternative possibility is for the enzymes also to be covalently bonded to the carrier (e.g. polystyrene or epoxy resins such as EUPERGIT® ~~Eupergit®~~). An enzyme which has been bound to a carrier in this way, for example, can be dried by lyophilization.--

Please amend the Specification on Page 14 by amending the paragraph in lines 1 to 5 to read as follows:

--Depending on the enzyme, the enzyme/substrate ratio, calculated as molar ratio between enzyme and dioxolanone/oxathiolanone derivative, is usually between ~~1:1 000 and 1:50 000 000 or more, preferably from 1:10 000 to 1:5 000 000.~~

1:1,000 and 1:50,000,000 or more, preferably from 1:10,000 to 1:5,000,000.--

Please amend the Specification on Page 15 by amending the paragraph in lines 1 to 2 to read as follows:

--The nucleophile/solvent ratio (v/v) is in this case preferably in a range from ~~1:10 000 to 1 000:1.~~ 1:10,000 to 1,000:1.--

Please amend the Specification on Page 19 by amending the paragraph in lines 7 to 12 to read as follows:

--50.0 g (0.27 mol) of racemic (4-oxo-1, 3-dioxolan-2-yl)methyl 2-methylpropanoate ($X = O$; $R^1 = H$; $R^2 = CH_2 - O - (CO) - CH(CH_3)_2$; $R^3, R^4 = H$) are dissolved in a mixture of 185 ml of MTBE and 185 ml of methanol ($Nu = OCH_3$) in a 1 l 4-necked flask. 2.6 g of ~~Novozym® 435~~ NOVOZYM® 435 are added to this solution, and the mixture is stirred vigorously.--

Please amend the Specification on Page 20 by amending the paragraph in lines 9 to 19 to read as follows:

--50.0 g (0.27 mol) of racemic (4-oxo-1, 3-dioxolan-2-yl)methyl 2-methylpropanoate ($X = O$; $R^1 = H$; $R^2 = CH_2 - O - (CO) - CH(CH_3)_2$; $R^3, R^4 = H$) are dissolved in a mixture of 185 ml of MTBE and 185 ml of methanol ($Nu = OCH_3$) in a thermostated 0.6 l glass flask. A separate glass column is packed with 1.3 g of ~~Novozym® 435~~ NOVOZYM® 435, and the substrate/solvent mixture is pumped via a tubing system through the glass column (flow rate 600 ml/h). The reaction is stopped (after ~ 25 h) by terminating the pumping, and the crude product is purified as described in example 1.--